XML 66 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-based Compensation -Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Options    
Outstanding as of December 31, 2022 (in shares) 3,356,937  
Sesen Bio options assumed in the Merger (in shares) 765,223  
Exercised (in shares) (128,716)  
Granted (in shares) 2,984,152  
Forfeited (in shares) (114,454)  
Expired (in shares) (839,772)  
Outstanding as of September 30, 2023 (in shares) 6,023,370 3,356,937
Exercisable as of September 30, 2023 (in shares) 2,516,594  
Vested and expected to vest at September 30, 2023 (in shares) 6,023,370  
Weighted average exercise price    
Outstanding as of December 31, 2022 (in USD per share) $ 1.01  
Sesen Bio options assumed in the Merger (in USD per share) 27.94  
Exercised (in USD per share) 1.29  
Granted (in USD per share) 6.93  
Forfeited (in USD per share) 5.80  
Expired (in USD per share) 29.48  
Outstanding as of September 30, 2023 (in USD per share) 3.94 $ 1.01
Exercisable as of September 30, 2023 (in USD per share) 1.16  
Vested and expected to vest at September 30, 2023 (in USD per share) 3.94  
Share based compensation arrangement by share based payment award options grants in period weighted average grant date fair value (in USD per share) $ 4.29 $ 1.46
Weighted average remaining contractual term (years)    
Outstanding as of September 30, 2023 7 years 9 months 18 days  
Exercisable as of September 30, 2023 6 years  
Vested and expected to vest at September 30, 2023 7 years 9 months 18 days  
Aggregate Intrinsic Value    
Exercised $ 134  
Outstanding as of September 30, 2023 5,929  
Exercisable as of September 30, 2023 4,950  
Vested and expected to vest at September 30, 2023 $ 5,929